Shire’s strong Q3 revenue growth of 3.6% (reported) to $1.7bn was driven by the better than expected performance of Vyvanse (+20%, benefiting from an additional indication for binge eating disorder), the Hereditary Angioedema portfolio Cinryze (+29%) and Firazyr (+25%) and higher royalties acquired with the NPS acquisition (pertaining to Sensipar). The NPS consolidated drugs Gattex (Revestive ex-US) and Natpara showed a healthy pick-up. The growth, however, was pulled down by generic co
30 Oct 2015
Strong results (without Intuniv) as Lifitegrast data brings relief
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong results (without Intuniv) as Lifitegrast data brings relief
Shires Income PLC GBP (SHRS:LON) | 226 5.6 1.1% | Mkt Cap: 93.3m
- Published:
30 Oct 2015 -
Author:
Kamla Singh -
Pages:
2
Shire’s strong Q3 revenue growth of 3.6% (reported) to $1.7bn was driven by the better than expected performance of Vyvanse (+20%, benefiting from an additional indication for binge eating disorder), the Hereditary Angioedema portfolio Cinryze (+29%) and Firazyr (+25%) and higher royalties acquired with the NPS acquisition (pertaining to Sensipar). The NPS consolidated drugs Gattex (Revestive ex-US) and Natpara showed a healthy pick-up. The growth, however, was pulled down by generic co